CA
NZ
UK
AU
IND
US
…
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ABVC Biopharma Inc is a clinical-stage biopharmaceutical company listed on NASDAQ that develops therapeutic candidates and drug-delivery technologies across multiple therapeutic areas. Long-term growth may be driven by advancement of its clinical programs, regulatory approvals, and potential partnering or licensing arrangements, so investors may find exposure to milestone-driven upside attractive.
Key risks include clinical and regulatory failure, significant financing and dilution requirements, intense competition from larger developers, and limited liquidity and public information typical of small-cap clinical-stage biotechs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.35M | -5.37M | -8.02M | -15.51M | -11.21M |
| Minority interest | 0.47M | 0.36M | 0.39M | -0.11M | -0.80M |
| Net income | -7.91M | -4.90M | -7.79M | -16.31M | -12.04M |
| Selling general administrative | 7.03M | 5.03M | 5.55M | 13.10M | 11.05M |
| Selling and marketing expenses | - | - | 0.03M | - | - |
| Gross profit | 0.80M | 0.51M | -0.15M | 0.68M | 0.35M |
| Reconciled depreciation | 0.50M | 0.20M | 0.03M | 0.02M | 0.01M |
| Ebit | -7.15M | -4.54M | -6.71M | -15.11M | -11.35M |
| Ebitda | -6.65M | -4.34M | -6.33M | -14.82M | -11.13M |
| Depreciation and amortization | 0.50M | 0.20M | 0.38M | 0.29M | 0.22M |
| Operating income | -7.15M | -4.71M | -6.77M | -15.11M | -11.35M |
| Other operating expenses | 7.15M | 5.21M | 6.92M | 16.08M | 11.70M |
| Interest expense | 0.42M | 0.83M | 1.31M | 0.29M | 0.23M |
| Tax provision | 0.02M | -0.11M | 0.26M | 0.80M | 0.83M |
| Interest income | 0.17M | 0.09M | 0.19M | 0.19M | 0.04M |
| Net interest income | -0.25M | -0.74M | -2.31M | -0.11M | -0.18M |
| Income tax expense | 0.02M | -0.11M | 0.26M | 0.80M | 0.83M |
| Total revenue | 0.80M | 0.51M | 0.15M | 0.97M | 0.36M |
| Total operating expenses | 6.65M | 5.21M | 6.62M | 15.80M | 11.70M |
| Cost of revenue | 0.50M | 0.00M | 0.30M | 0.29M | 0.01M |
| Total other income expense net | -1.20M | -0.66M | -1.26M | -0.40M | 0.13M |
| Net income from continuing ops | -8.38M | -5.26M | -10.91M | -16.31M | -12.04M |
| Net income applicable to common shares | - | - | - | -16.42M | -12.84M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 21.06M | 7.54M | 14.94M | 9.86M | 13.70M |
| Other current assets | 1.76M | 0.10M | 0.10M | 0.15M | 1.95M |
| Total liab | 7.76M | 6.82M | 6.36M | 6.24M | 4.83M |
| Total stockholder equity | 11.11M | 1.23M | 8.84M | 3.10M | 8.84M |
| Other current liab | 4.27M | 3.51M | 3.70M | 3.55M | 1.69M |
| Common stock | 0.03M | 0.01M | 0.01M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.01M | 0.01M | 0.03M | 0.03M |
| Retained earnings | -76.86M | -68.95M | -65.42M | -54.90M | -38.48M |
| Other liab | - | - | - | - | 0.01M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | - | 1.14M |
| Cash | 0.68M | 0.86M | 0.72M | 0.09M | 5.83M |
| Total current liabilities | 6.16M | 6.56M | 5.93M | 5.82M | 3.69M |
| Current deferred revenue | - | 0.08M | 0.08M | 0.01M | 0.01M |
| Net debt | 2.79M | 2.34M | 1.73M | 2.97M | -2.72M |
| Short term debt | 1.87M | 2.97M | 2.04M | 2.26M | 1.99M |
| Short long term debt | 1.55M | 1.79M | 1.47M | 1.89M | 1.83M |
| Short long term debt total | 3.47M | 3.20M | 2.45M | 3.05M | 3.11M |
| Other stockholder equity | 87.46M | 69.69M | 73.74M | 57.45M | 46.76M |
| Property plant equipment | - | - | - | - | 2.00M |
| Total current assets | 2.50M | 2.18M | 1.66M | 2.99M | 9.63M |
| Long term investments | 1.88M | 2.26M | 2.53M | 0.84M | 0.93M |
| Net tangible assets | - | - | - | - | 8.84M |
| Short term investments | 0.06M | 0.06M | 0.08M | 0.08M | 0.11M |
| Net receivables | - | 1.16M | 0.76M | 1.37M | 1.71M |
| Inventory | - | - | - | 1.31M | 0.03M |
| Accounts payable | - | - | 0.11M | - | 0.00M |
| Accumulated other comprehensive income | 0.49M | 0.48M | 0.52M | 0.52M | 0.54M |
| Non currrent assets other | 1.93M | 1.95M | 1.42M | 1.34M | 0.16M |
| Non current assets total | 18.56M | 5.36M | 13.29M | 6.87M | 4.07M |
| Capital lease obligations | 1.92M | 0.64M | 0.81M | 1.16M | 1.47M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -0.36M | -1.72M | -0.81M |
| Change to liabilities | - | - | - | 0.00M | -0.02M |
| Total cashflows from investing activities | -1.21M | - | -0.36M | -1.72M | -0.81M |
| Net borrowings | 0.34M | 0.02M | 0.46M | - | -0.27M |
| Total cash from financing activities | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
| Change to operating activities | - | - | - | 1.25M | -1.44M |
| Net income | -7.91M | -5.26M | -7.79M | -16.31M | -12.04M |
| Change in cash | 0.46M | 0.15M | -0.67M | -5.17M | 1.56M |
| Begin period cash flow | 0.86M | 0.72M | 1.39M | 6.57M | 5.00M |
| End period cash flow | 1.33M | 0.86M | 0.72M | 1.39M | 6.57M |
| Total cash from operating activities | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Issuance of capital stock | 3.31M | 0.03M | 1.05M | 3.66M | 11.12M |
| Depreciation | 0.50M | 0.20M | 0.38M | 0.02M | 0.01M |
| Other cashflows from investing activities | -1.21M | - | -0.34M | - | - |
| Change to inventory | -0.01M | 0.00M | 0.07M | 0.03M | -0.03M |
| Change to account receivables | -0.14M | -0.29M | 0.23M | -0.61M | -0.12M |
| Sale purchase of stock | 0.00M | -0.01M | 0.00M | - | - |
| Other cashflows from financing activities | 4.64M | 1.94M | 2.59M | 0.35M | -0.61M |
| Change to netincome | - | - | - | - | 6.84M |
| Capital expenditures | 0.01M | 0.00M | 0.02M | 0.12M | 0.02M |
| Change in working capital | -0.62M | -0.41M | 0.31M | 0.64M | -1.61M |
| Stock based compensation | 4.14M | 2.77M | 0.19M | 7.04M | 5.31M |
| Other non cash items | -2.37M | 0.88M | 2.73M | 0.35M | -0.09M |
| Free cash flow | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABVC ABVC Biopharma Inc |
-0.04 3.67% |
1.05 | - | - | 111.69 | 2.55 | 184.61 | -1.90 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
510 668 0881
16
| Name | Title | Year Born |
|---|---|---|
| Mr. Eugene Jiang | Chairman & Chief Bus. Officer | 1986 |
| Dr. Howard Doong M.D., Ph.D. | Pres & CEO | 1957 |
| Dr. Chi-Hsin King Ph.D. | Chief Scientific Officer | 1948 |
| Dr. Tsung-Shann Jiang Ph.D. | Chief Strategy Officer, Member of Scientific Advisory Board & Director | 1954 |
| Mr. Leeds Chow | Chief Financial Officer | NA |
| Mr. Eugene Jiang | Chairman & Chief Business Officer | 1986 |
| Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer | 1986 |
| Mr. Leeds Chow | CFO & Principal Accounting Officer | 1989 |
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer & Director | 1954 |
| Dr. Uttam Yashwant Patil Ph.D. | CEO & Interim CFO | 1986 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...